{Reference Type}: Journal Article
{Title}: The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial's Impact.
{Author}: Arter ZL;Nagasaka M;
{Journal}: Lung Cancer (Auckl)
{Volume}: 15
{Issue}: 0
{Year}: 2024
暂无{DOI}: 10.2147/LCTT.S443099
{Abstract}: Targeted therapies, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), have revolutionized the treatment landscape for EGFR-mutant non-small cell lung cancer (NSCLC). However, the emergence of resistance to EGFR TKIs especially the third generation TKIs such as osimertinib remains a major clinical challenge. As a broader strategy for combating resistance, several clinical trials have explored the efficacy of immune checkpoint inhibitors (ICIs)+chemotherapy in EGFR-mutated NSCLC. Until now, the ORIENT-31 and IMpower150 trials suggested that ICIs+ chemotherapy may be more effective than chemotherapy alone after failure of EGFR-TKIs (although ORIENT-31 was negative for overall survival [OS] and IMpower150 was a subset analysis, so the study was not powered to detect a difference); however, the CheckMate-722 trial yielded disappointing results. Thus, the results of this global trial KEYNOTE-789 were highly anticipated.